Clinical Trial Update: Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine in combination with imatinib mesylate for recurrent or metastatic non-small cell lung cancer was terminated, with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Gleevec (Imatinib)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-05-22